<SEC-DOCUMENT>0001193125-13-463659.txt : 20131205
<SEC-HEADER>0001193125-13-463659.hdr.sgml : 20131205
<ACCEPTANCE-DATETIME>20131205165235
ACCESSION NUMBER:		0001193125-13-463659
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20131205
DATE AS OF CHANGE:		20131205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		131260329

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d638316d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospects Supplement No. 12</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(to
Prospectus dated May&nbsp;30, 2013)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424 (b)(4)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-187508</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g638316g01e05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;), and by that certain Prospectus Supplement No.&nbsp;11 dated November&nbsp;21, 2013
(&#147;Supplement No.&nbsp;11&#148;, and together with Supplement No.&nbsp;1, Supplement No.&nbsp;2, Supplement No.&nbsp;3, Supplement No.&nbsp;4, Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, Supplement
No.&nbsp;9, and Supplement No.&nbsp;10, the &#147;Supplements&#148;), which form a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information
in the Prospectus and the Supplements with the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on December&nbsp;5, 2013 (the &#147;Current Report&#148;).
Accordingly, we have attached the Current Report to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus
supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our
Common Stock and 6,250,000 shares of Common Stock underlying the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with
the Prospectus and the Supplements. This prospectus supplement updates and supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this
prospectus supplement, you should rely on the information in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global
Market under the trading symbol &#147;ABIO.&#148; On December&nbsp;5, 2013, the last reported sale price of our common stock was $1.65 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 23 of our quarterly report on Form 10-Q for the quarterly period ended September&nbsp;30, 2013 before you decide whether to invest in shares of our common
stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is December&nbsp;5, 2013 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;5, 2013 (December 4, 2013) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;4, 2013,
ARCA biopharma, Inc. (&#147;ARCA&#148;) announced that its Investigational New Drug application for Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, a pharmacologically unique beta-blocker and mild vasodilator being developed for
atrial fibrillation, has been accepted by the U.S. Food and Drug Administration and is now active. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on December&nbsp;5, 2013, ARCA announced that Laboratory Corporation of America
(LabCorp<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) has submitted an Investigational Device Exemption application to the U.S. Food and Drug Administration for the planned companion diagnostic test for Gencaro. The press release is
furnished as Exhibit 99.2 hereto, the contents of which are incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces U.S. FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation&#148; dated December 4, 2013.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces IDE Submission to U.S. FDA for Gencaro Companion Diagnostic Test&#148; dated December 5, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;5, 2013 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Christopher D. Ozeroff</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: SVP and
General Counsel</P></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces U.S. FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation&#148; dated December 4, 2013.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces IDE Submission to U.S. FDA for Gencaro Companion Diagnostic Test&#148; dated December 5, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g638209g82c54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES US FDA ACCEPTANCE OF GENCARO IND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPLICATION FOR THE TREATMENT OF ATRIAL FIBRILLATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, December&nbsp;4, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that the Company&#146;s Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Investigational New Drug (IND) application for atrial fibrillation (AF) has been accepted by the U.S. Food
and Drug Administration (FDA) and is now active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA plans to evaluate Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a
potential treatment for atrial fibrillation in the Phase 2B/3 GENETIC-AF clinical trial, which is expected to begin enrolling patients in the first quarter of 2014. ARCA has identified common genetic variations that it believes predict individual
patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Michael&nbsp;R. Bristow, Founder and CEO of ARCA, and a pioneer of beta-blockade development commented, &#147;At ARCA, we believe a personalized
medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. If the GENETIC-AF trial
successfully confirms the atrial fibrillation data analysis from a prior Phase 3 clinical trial, Gencaro has the potential to be the first genetically targeted treatment for the prevention of this important cardiovascular disorder and provide a much
needed treatment option for patients in an area of high unmet medical need.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GENETIC-AF Clinical Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to Toprol-XL for prevention of AF in patients
with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an
adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3
study by enrolling an estimated additional 420 patients. The Company anticipates that patient enrollment in GENETIC-AF will begin in the first quarter of 2014. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations
that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF
trial. For more information please visit <U>www.arcabiopharma.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial
fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g638209g82c54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES IDE SUBMISSION TO US FDA FOR GENCARO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANION DIAGNOSTIC TEST </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, December&nbsp;5, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) (NYSE: LH) has informed ARCA that LabCorp has submitted an Investigational Device
Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for the planned companion diagnostic test for Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), a pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). If accepted by the FDA, the IDE will allow the companion diagnostic test to be used in the planned GENETIC-AF clinical trial. ARCA&#146;s Gencaro Investigational New
Drug (IND) application for AF has been accepted by the U.S. Food and Drug Administration (FDA) and is active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA has identified common genetic
variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. LabCorp and ARCA have developed the companion diagnostic test for Gencaro to identify
patient genotypes based on these genetic variations of the beta-1 cardiac receptor. LabCorp will provide the patient genetic testing for ARCA&#146;s GENETIC-AF clinical trial of Gencaro, which is expected to begin patient enrollment in the first
quarter of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GENETIC-AF Clinical Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to Toprol-XL for prevention of AF in patients
with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an
adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3
study by enrolling an estimated additional 420 patients. The Company anticipates that patient enrollment in GENETIC-AF will begin in the first quarter of 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to
developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
&#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment
in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future
treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive
products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g638209g82c54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g638209g82c54.jpg
M_]C_X``02D9)1@`!`0$`E@"6``#_X0!:17AI9@``24DJ``@````%``$#!0`!
M````2@````,#`0`!`````/_]_1!1`0`!`````?_]_1%1!``!````$1<``!)1
M!``!````$1<```````"@A@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,
M"PL,&1(3#Q0=&A\>'1H<'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_;`$,!"0D)#`L,&`T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_``!$(`$4`R`,!(@`"$0$#$0'_
MQ``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#
M!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!
M`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<`
M`0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/9-;UP:
M=B"`*]P1DYZ(/?WKG/[7U29\F[EY_NX'Z"C55:;7+KJ3YF/Z5;LK-7PC?*_8
MG^1KX[$8C$XK$2C&323LK:'H0A"G!.VHR.YU1I%0W<V20/O4PWFJ8)^V3<#)
M^:MZ.T2)H'E*HZ'#!CU`Z$?RIC:?F#;'M8N<LV>%`]_UKI>!K<NDW?U?D1[6
M-]C`36]4MY`WVIV]5?D&NKTC5DU2W+8V3)@.G]1[5S-[:KDK$"V.^.3_`/6J
M?PMN359DSP83D?B*SR_$8BCBHTIR;B]-=?N*JPA*#DEJCK\T9HHKZPX"IJNI
M0Z1I5UJ%P3Y5O&78#J<=`/<G`_&F:/JL&MZ1:ZE;9$5PFX*>JGH0?<$$?A7)
M>/UNM>GA\,:>?WIA>]GY_A0$1K_P)\?D#67\(-:\RUO-%F?YHCY\*GKM/##\
M#@_\"-`'I^:HZIJ9TNV686-[>`MM*6D0D8<=2,CBKU%`'$O\5/#T3LDR:A%(
MAPT<EOA@?0C/%75\<PO#YZ:!XA:$C(D%@<$>O7I7FWQ#1?\`A9!^4?-Y&[WX
M`KW*@##T7QAH>OR^18WH-P!DP2*4?WX/7\,UN9KQ'XGP+I7C>*\L6,$\L*7)
M9#@B0,PW#_OD5[/93/<6%O-(NUY(E=E]"0"10!*\BQ1M)(ZHBC+,QP`/4FN7
MD\?Z7+>&STF"\U>X'4646Y5]RQ(&/?I7"^*-<O?''BN/PWIDI2P$WEDCI(5Y
M9V]5&"0/;/4\>J:-HUCH.FQV-A"(XEZG^)V[LQ[DT`9,OB;68(VEE\(ZCY8&
M3Y<T4C?]\ALFJVB_$;2=;U:+2X[:^M[N4LH6>-0`0"2#ACCH>U=?7,:[X9%S
MXATG7;&%!>VURHN""%\R$\$GU('3VR/2@#I\T9HI"0`22`!U)H`Q]4\366DZ
MYIFE7!/G7[$*P(PG89^IX%;.:\(\8F^U*5?%\;E;6:[:WM2O\"1_<;\2'/U'
MO7LN@:JFMZ#9:BA'[^,%P/X7Z,/P((H`TQUHH'6B@#B+U`VMW664?O#US6Y8
M!?E1IHI%Z!6!)_#(KG]0<+KEUG./,/2M;3[KCY-D2C[SXR?U_I7R>"J1CB)I
M]W^9WU$W!#;&Y\^4RRG+,<GVK6,T1D15`.XA2/6LV334FF$]I-Y/FL?W;C()
M]1CI4]O$EHJRRSEV;*AE'"'Z=Z[\.ZM/W9K3OI_P^IC/E>J(=0`=2OVB(+_<
M4$#]!57PXH76)<,#^Y/3ZK2ZC=9)$JJ6_OKQGW]#4?AE@VL2XZ>2?YK7&YQE
MCZ:7<U2:I,ZZF2RQP0R32N$CC4L[$\``9)I]<;\0[Z8Z9:Z#9,/MNKS"`#^[
M'D;C].0/H37U)PE7P9JEA<S:IXAO[ZSAN=1GQ%').H:.!/E0$$\?UP#7$3WE
MMX3^*'VRSN(I+!YM[-&X9?*D^\./[I)X_P!D5ZW;^%=!M[:*$:/8.(T";GMD
M9FP,9)(Y-</\4O#%E;Z);ZGI]E!;?9Y-DRP1*@96X!.!V(`_X%0!Z@"",@Y!
M[BBN6^'VL_VSX0M6=@T]M_H\OU7H?Q7;^.:ZF@#P[XC-M^(NX*6($!VKU/`X
M%=WJOQ*L]'(2\T36()F&46:%4#?0[C^F:X7XB?\`)25_[8?TKUCQ/X?M_$NB
M36$V%<_-#(1GRW'0_P!#[$T`<;I'A:3QGJL?BO6YH&M90&M[*%BX"J>%<D=N
M<@=23TZ5W>N7$EIH&HW$)Q)%:R.A'8A217DW@+Q%/X5UZ;0-6S%;RR[&#GB&
M7IG/]T\#/T/3->R7$$=S;2V\HW1RH4<>H(P:`/&/A#`DGBJXD;EHK-BOU+*,
M_E_.O:Z\)\+3/X*^(?V3428TRUK(YX&UL%7^A(4_0U[M0`4453U;4[;1M*N=
M1NV(A@3<V.K>@'N3@#ZT`7*Y3X@:JUAX>^Q021I=:DXM(B[;0H;AF)[`#C/;
M(KJ(9#+!'(49"ZAMK=5R.A]ZX6VBA\7_`!#O;BXBBN-+T>/[-&DBAE>9OO'!
MX.,$?@M`%C7;;0;GP))H=MJ=@3!;@6^+A,ET&1W[D8/U-87P?UK?#>Z-(XRA
M^T0@]<'`8?GM/XFN^_X1O0?^@)IO_@)'_A7D6HK_`,(+\45GC`2T,HE"@8'D
MR9#`#V^8#_=%`'N0ZT4BD'!!!!Y!'>B@#C_$FFR07CWB`F&4Y8C^!O?ZUEPW
M3+A<\#H*]$8!@00"#P0:H-HFFNV39Q@_[.1_*OGL5DLYUG5H2M?HSKAB4H\L
MD<[#J8%Q$<_*A`'TJ)M1_=LA;AN?Q'^373?V'IHZ6B_]]'_&C^PM,_Y]%_[Z
M/^-)Y;C6K<\?Q_R#VU+LSB9KEI!C/'\JZ/POI\D*R7DJE?,7;&#U(ZD_RK6B
MTC3X7#I:1AAR"1G'YU=K7`Y/*C55:M*[6UA5<0I1Y8HIZG=7=G:>99Z?)?3%
M@/*214P.>26(&/UYKSLZ?XUE\:P>)+O0X95@!2.U6[C&Q"",`YZ_,3GN?3MZ
MA52/4(9;][-`YDC7+DK@+^?UKW3E'V,\]S9QS7-H]I,V=T+NK%>?520?7\:Y
M[Q<^L7NGWNDV&@-=I<1;!</<1H@R.N"<Y'X<UU-007D%S+-%$^YX6VN,$8-`
M'E?A30O&_A&[DEATF*YMY@!-`;J,;L="#G@C)_.O0Y=5U5=+BN8_#\[W3N5:
MU^TQ`H.?F+9QCZ<\UL44`>-:]X3\9Z_K\FKOI,,#L5*1"Y0[`H&!G//2O2]%
MU+6KM_*U;0FL6"9,RW*2(S<<``Y&>3^'6MJD)VJ2<X`SP,T`>>_$7P//KDD.
MIZ3`KWPQ'-'N5?,7LV20,CI]/I5O0+SQKI=A%::IH`O5B4*DT5Y&)-HZ!@3@
MGWR/QZUUUE?Q7XD:`/L1MFYAC)]JM4`<SXM\%V'BN!6D)M[Z-<1W"C)Q_=8?
MQ#^7;OG(T>7QCX8B6PO]+_MBQB&(KBUF7S%7L,-@M_GDUWM%`'-'Q7=NN(/"
MNMM)_=DB2-<_[Q:N7U71/&7C'4K7^T[2WT_2HIE<VWGACMSR3MSN;&1V%>FT
M4`<WXAO_`!(JSV>A:+O<KA+R2XC55R.H4G)(]\<^M87@:R\1>&;9M.O=!,D<
M]QYC74=U&2N0`2PSDXQGC\J]!HH`9*S)$[I&9&520@(!8^G/%>7>--#\3>+[
MNUEB\/"T6W1EW27<19\D'G!X`Q^IKU2B@#B_"<_BW3;>UTO5]$\V"/;&MW%<
MQY1.GS+GG`[CG`Z$T5VHZT4`(>M%!ZT4`%%%%`!1110`V2188GD<X1%+,?0"
MN9M;^YMK.?4Q:J_GR@NS-CC.`J^N/7^=;&MPW%QICQ6Z%V9E#*#@E<\XS2):
M-<M`98?(MH,&.`D$EAT+8XX["@"W<SBW@,A4G'X`>Y/85#IEU)>6"7,L2Q-)
MDX'IV-0ZS%<W-O%;P1LZ22`3%6`(7\:LO!(^G/;Y17:,H-HPJ\8&/84`49=9
M?[-->0Q*UI"VW<QP9.<';[>YZUI2W"QVIN-K,H7=@8SC\:QUT^>XL+33FA,%
MO&`9V8CYR.<+@]SSFI]?E86"VD`)EN6$2*..._\`A^-`%*VU.\MH$O;A0]O=
M3X"ESN0'.,#ICBMG4KK['IT]P/O*OR_4\#]:J&R:[EM4:%H;2UPRJ^-SL!QP
M#T'ZU)JEI)?2VD&S-OYF^8YQP!P/QH`SK2[GTS2[+;;*T,CA68MAF+<Y`]/K
MUK?FEC@B:25@J+U-4%BFOYH)+FW-O'`Q<1E@Q9NQX[#^=)J"73ZC9M';^=!'
MEB"X4!^@)^E`"RZA<B]M;:.W53,2QWMEE0=20.A].:?JVH/IUHTR1!R.['"C
MG'Y^U5=,M;U=3NKJ[10S-M#GN@Z!0.@Z=?2I]1LY+^\M(F0_9$8R2G(P2.@Q
M0`^UN[RXGC+6@2U=-PD+\Y^GH?\`/I45_JS6EY;P)`7\Q]ISG<1WVCOUZUJ5
MD+;7)N[O49(-TZ@QVL1(X7UZ]_\`&@!JZS<&\NK9K:/,*[MPD^5>,G<<=O;_
M`.O5[3;J2]T^*XEC$;."=HZ8SP:RI-,N8M,BMHXVDDN)`UVZL`<=2,G_`#^=
M:LZW$>ER)"%^T",A`G`![8SZ4`-N-16*.=XT$BP`F1BVU01_"#@Y-26$LT]E
M%-<(J2.-VU>@!Z?I6+-97\UM86WV0+;*1YL>\9)'=C[G/3/Y\5T*!@BAR"V.
M2HP,^U`#QUHH'6B@`Q1BBB@`Q1BBB@`Q1BBB@`Q1BBB@`Q1BBB@`Q5"33Y9=
M3AO&N%Q$"%C\O@`]>_7WHHH`OXHQ110`8HQ110`8HQ110`8HQ110`8HQ110`
,8HQ110`8HHHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g638316g01e05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g638316g01e05.jpg
M_]C_X0Y317AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````1````L(=I``0````!````Q````/``+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHQ,CHP-2`P
M.3HS,3HS,P!*86-K:64@36ER;VYE<V-U```````#H`$``P````$``0``H`(`
M!`````$```"MH`,`!`````$````\``````````8!`P`#`````0`&```!&@`%
M`````0```3X!&P`%`````0```48!*``#`````0`"```"`0`$`````0```4X"
M`@`$`````0``#/T`````````2`````$```!(`````?_8_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"``W`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#M.I=8RGWNQL,^DRL[7V`2YQ_D*LR[J3QN&59`
M\"$.BL/N?+H)L=K\UJMKJIK%MT$V#9#(BT']UH^AL7/PEGYC)*<LDX0'8MPB
M&.(`C;2)ZG+1]IM$B9D(3<_JE+@X7NL(_-?JT_UEM>DQ[`YS367-#`\:Z?N1
M^\L[.QPS1T5@<5-U,?O/*=GPY\<1.&69\3.?Y(A*$CPF(=;IV<S.QVW@%KN'
ML\'*VL?ZNB*+Q,@6Z?<M<+6Y3++)@QSEK*4;):^2(C,@,,FZK'ILR+G;*J6.
MLL<>`UHW.<LWZK]?KZ_TEG4&UFAY<^NVDG<6.8?H[OY5>RS^VJGUHM.9?T_Z
MNU_]ZMCCED'48E`]7)_J^N[TZ/[:P/J9>[I'UJZI]7[3%=KBZAIXFOW5Q_QN
M*[_P)6%CWY6!UKZS9_1766Y72+;>GL>UC<RFVMVCM&OLH<6VU>_V+?'"P?KY
M`^J?4?ZC)_[<K24@P/K9U/JM!R>F="ONH#BT6VW54AQ:=KO3W.>Y_N1.G_7/
M!R.I?LC/HNZ5U.=K<?)`VO)U:*,FLNIMW_F*'^+W7ZJ8WAONC_MRQ<Y_C`8[
M/^M?3NG8`]7J!J;[6:EA]3U*[+(_F_39O?ZCDE/I$B%B=8^MO3.E9#,&+,WJ
M=O\`-8&*WU+3/T39PREG\JQR)]:.L.Z/T7(S:H-^E6/.OZ5Y]-IV_G;/IK"_
MQ<='97@6=<OFW.Z@]Y]=QW/-8=M>[>[\ZZUKK+$E.F.H_72QHLKZ/C4,Y]*[
M+FPC^M32ZIO^<@X?UQRG=<HZ'U3I-O3LK(W>F\V-MJ(:"[?6]@;O:Z/_`$HN
MF(T5'J'2<?J%V'?82R[I]XOHL;]+B+*O^*N9['I*;S>/'S0.H9E6!AY&;<?T
M6-6ZU_;1HW;1_61YTXY[+G/K*#U3J>!]66R<?)#\OJ1:8(QJO;35_P"A.6ZM
MO_6DE.E]7>L,ZUTC'ZDUHJ-S3ZE.[=Z;P8?4YT-]S5I+@OJ#E6X'5NJ?5_)^
MFVQ]M0[;F'T[=O\`QM?I6KO6\)*?_]#J\5Y%CS[?INU/;57\JNRZJNW&`M-#
MCO:QNT&1,U_O[%EWUV8N8^JT1+BYI.F]I,^U6J<\@;W&"&[*P#HV='$?RESF
M#)&''ARZ<1K3^IJ)-Z<2>&4=6YCY&3>/38QS&R"Y[A`'^<H9UC'%PKV$\%FR
M'`CG>H6Y^^&NES36`03PX?GM_E*AE91>-UCM&C5YTT_EJ7-S$1BX`3/Q*V.,
MF5R'#3K?5XS3D'_A?X+6Y$>*R^@TV589LL!:;W;VM/9O#?\`.6=]:NM9XP\O
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M>K],S*&5.V8N2VHO86O/MKO]/<ZIU>[^<_FU9^N?4+<SIN7T3`P<O+RK',8Y
M]=3A6P`MM-GKOVUV;8V^Q)3F?5_HO4L[ZHUY/2NHY.'G3::JF/B@EKW_`*/T
MG-]GJ_Z7_2(G^+GJ6'.3T^^D4]9+G/MR;-;[P'?I6WVO][LC%?['U?\`7%;^
MI>==TWI]'1>H=/R\7(]5X98ZDNJ=ZCG6M?ZS-S:_I?GJE]=/J[GX_4Z?K#T*
MM[L@V--[*&[G-M;[69+6#Z5=S/T&8DIU/\8U#[?JVY[)BB^JU\=FR6;_`.SO
M5CZAY%5WU6PPSG'WTO'@YKW;I4^G=9'5JAT_JG3,G"OR6.;=1?4321'Z0-R6
M37M?_+]ZP<3I77_J7GVV=.HLZST/)(-M-9'VBN/H.97_`(5];/9[?Y])3WDI
MB]@:7$@-;J2>!'BL2OZX]`>R7WV4OX=5;1:VQI_=<STUB]<ZAU;ZR&GI'3^F
MY=?2,FYC<_.N8:M](=N?7379LM])^W]);M24]FY[`TN+@&@;BZ=-O[VY<?T!
MO7>IY&=]9>GV8K*NJ6AF-]I8][ABX^ZFGT_2>S9Z[_4M<Q%^M_5L^[IV5T;H
MG3\N^ZP&B[(KJ+:ZZR-MOI6/V^J]S/8STUL_5_*Q+.GUXN)CW8C<%C*33D5.
MJ+8;Q[@&V?UZTE/$_66OJ70?K'@]?RG4FRYP-KL9KF-(J'IY%;FV.>YS[L:S
M_P`#7I-=C'L;8PAS'@.:X=P=6E<G]?7-S^GOZ7CX>3E]0J?7=1Z51+`9]SO7
M=^B_F39[=RC]5NMY^!T^GIG6>FYM#\<"O'R?2=8Q["=M;7NJW^G96WV>])3_
M`/_1]-OQ,?):&WUML`XD:C^JY5OV%TSCT?\`I._O6A"4**>#',W.$9'O(6D2
M(T!+0/1.F]ZO^D[^]/7T;IU;P]E(+@9&XEP!\=KE>A)`<K@!L8H#_!">.7<L
M8(_N0,W-9A4&^QKGB0P-8))<X[6<_P`I63HLG/L.1U*G&80*\,?:,A[OHL,'
MT7/_`#7.;[K&M4RUU&DD#<(,"6SP4*K*KLR+<9C7A]&W<2"&G=K['_GJM@Y-
MSNGF_(>#!>YEKQM!K'T+GM;^\U1P\NYO3+,W-<X@[K6L<T-<VL_S=;FC]Y)3
MHSYIIC3\5E49><,G!;>?TF:'OMQ@!MKK#=S8=_)<?[:EU`/RNI8^$'EE-3?M
M=CV:.!:=M0GZ.W>DIU-3P56Q,ZO*LO8QKV_9G^F][Q$N&KMJK8'47NZ-^T,L
MCVM>]SP(#FL+O3?M_EL"J8W[0QL;!(=LORKBZV@PXN;9-MUMGYVZIO[G\VDI
MW9GNEYA5,G,V6FEA`+&^I?:[Z-=?\K_A7_X-B'TRS*R,=^5:[=Z[B[&K>-NV
ML>VO=M_TG\XDIT)[SPF^)63T^WJ.=4;VY.RD7GTG[!-E33M<TC\UG[C_`*:)
MFY.6WJ&-C8SFC=-MS2)`J&CK+7_F[G?S>U)3I?D26#5G]1NJ'I7$_:<C;A.+
M1+JFG]-;:W\W'V_0_P`(M7+R75N932W?D6SZ;3]%H'T[K?W:V?\`324V9'$I
MQ*SNFWWY5^1?ZF_$:?2QY``<6_SUWM_,]3VU+1`@>/FDI__2]527RJDDI^JD
ME\JI)*?JDK.LP^G'(R+[+O:2W[347@5[@!Z9M;_WUZ^9TDE/U!G48U^'95D6
M>GCN`WN#@T!H,_3_`'')/JPOL=E3RW[*6D6$NT@_2+K)7R^DDI^G,7&PZ+W%
MMOJY3JV[B]P=8*A]#:UOT:MRI8V/7DV9M^8]U#[7Q=3N#2,=@+:?6UW5,L_2
M/W^Q?."22GZ>R:<&["#+G-9AC8Z0X-9M:6NJ;N^CZ3O:E7C8]667OM-F1;N-
M8L<"6L.WU&8[?S:MR^84DE/TOEX/3;+<FR^XM]1K67M]0-:TQ^B>YOYMG^CW
MJPS'QOLCZ6/_`$)86O>':Q$%_J?F^U?,"22GZDQF8[<>MM!::&M`K+2"-H_E
M#Z2J6X?3G'-;9;#[V@Y9W@.;6!#6_P#`T[5\S))*?IG[+TPY%-_J"6T[**@\
M;#5^:]C/SOZZGDXN%;E^M=86VLI<U[`_:#4?IFUD_0:[\Y?,:22GZ?Z=CXF/
M0VO%L]5@:-K]P>2W79[F_F?N*VOE5))3_]G_[19*4&AO=&]S:&]P(#,N,``X
M0DE-!`0``````"0<`5H``QLE1QP"```"0;$<`E``$$IA8VMI92!-:7)O;F5S
M8W4X0DE-!"4``````!#L+?*F6SJ5DD(,*F+RV58@.$))300Z``````$5````
M$`````$```````MP<FEN=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN
M=&5E;G5M`````$EN=&4`````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L
M``````MP<FEN=&5R3F%M951%6%0````9`%(`:0!C`&\`:``@`$$`9@!I`&,`
M:0!O`"``30!0`"``-@`U`#``,``@`%``0P!,```````/<')I;G10<F]O9E-E
M='5P3V)J8P````P`4`!R`&\`;P!F`"``4P!E`'0`=0!P```````*<')O;V93
M971U<`````$`````0FQT;F5N=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F
M0TU92P`X0DE-!#L``````BT````0`````0``````$G!R:6YT3W5T<'5T3W!T
M:6]N<P```!<`````0W!T;F)O;VP``````$-L8G)B;V]L``````!29W--8F]O
M;```````0W)N0V)O;VP``````$-N=$-B;V]L``````!,8FQS8F]O;```````
M3F=T=F)O;VP``````$5M;$1B;V]L``````!);G1R8F]O;```````0F-K9T]B
M:F,````!````````4D="0P````,`````4F0@(&1O=6)`;^````````````!'
M<FX@9&]U8D!OX````````````$)L("!D;W5B0&_@````````````0G)D5%5N
M=$8C4FQT````````````````0FQD(%5N=$8C4FQT````````````````4G-L
M=%5N=$8C4'AL0'+````````````*=F5C=&]R1&%T86)O;VP!`````%!G4'-E
M;G5M`````%!G4',`````4&=00P````!,969T56YT1B-2;'0`````````````
M``!4;W`@56YT1B-2;'0```````````````!38VP@56YT1B-0<F-`60``````
M`````!!C<F]P5VAE;E!R:6YT:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL
M;VYG``````````QC<F]P4F5C=$QE9G1L;VYG``````````UC<F]P4F5C=%)I
M9VAT;&]N9P`````````+8W)O<%)E8W14;W!L;VYG```````X0DE-`^T`````
M`!`!+`````$``@$L`````0`".$))300F```````.`````````````#^````X
M0DE-!`T```````0```!X.$))3009```````$````'CA"24T#\P``````"0``
M`````````0`X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$"```````$`````$```)````"0``````X0DE-
M!!X```````0`````.$))300:``````-#````!@``````````````/````*T`
M```'`$0`4P!0`%\`,``P`#$````!``````````````````````````$`````
M`````````*T````\``````````````````````$`````````````````````
M````$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0``````
M`%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````
M0G1O;6QO;F<````\`````%)G:'1L;VYG````K0````9S;&EC97-6;$QS````
M`4]B:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG````````
M``=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG
M:6X````-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E
M`````$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4
M;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````/```
M``!29VAT;&]N9P```*T````#=7)L5$585`````$```````!N=6QL5$585```
M``$```````!-<V=E5$585`````$```````9A;'1486=415A4`````0``````
M#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````
M"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0`
M```)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L
M=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````
M3F]N90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P``
M```````,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG
M```````X0DE-!"@```````P````"/_`````````X0DE-!!0```````0````"
M.$))300,``````T9`````0```*`````W```!X```9R````S]`!@``?_8_^T`
M#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``W`*`#`2(``A$!`Q$!
M_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!
M`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#M.I=8RGWNQL,^DRL[7V`2YQ_D
M*LR[J3QN&59`\"$.BL/N?+H)L=K\UJMKJIK%MT$V#9#(BT']UH^AL7/PEGYC
M)*<LDX0'8MPB&.(`C;2)ZG+1]IM$B9D(3<_JE+@X7NL(_-?JT_UEM>DQ[`YS
M367-#`\:Z?N1^\L[.QPS1T5@<5-U,?O/*=GPY\<1.&69\3.?Y(A*$CPF(=;I
MV<S.QVW@%KN'L\'*VL?ZNB*+Q,@6Z?<M<+6Y3++)@QSEK*4;):^2(C,@,,FZ
MK'ILR+G;*J6.LL<>`UHW.<LWZK]?KZ_TEG4&UFAY<^NVDG<6.8?H[OY5>RS^
MVJGUHM.9?T_ZNU_]ZMCCED'48E`]7)_J^N[TZ/[:P/J9>[I'UJZI]7[3%=KB
MZAIXFOW5Q_QN*[_P)6%CWY6!UKZS9_1766Y72+;>GL>UC<RFVMVCM&OLH<6V
MU>_V+?'"P?KY`^J?4?ZC)_[<K24@P/K9U/JM!R>F="ONH#BT6VW54AQ:=KO3
MW.>Y_N1.G_7/!R.I?LC/HNZ5U.=K<?)`VO)U:*,FLNIMW_F*'^+W7ZJ8WAON
MC_MRQ<Y_C`8[/^M?3NG8`]7J!J;[6:EA]3U*[+(_F_39O?ZCDE/I$B%B=8^M
MO3.E9#,&+,WJ=O\`-8&*WU+3/T39PREG\JQR)]:.L.Z/T7(S:H-^E6/.OZ5Y
M]-IV_G;/IK"_Q<='97@6=<OFW.Z@]Y]=QW/-8=M>[>[\ZZUKK+$E.F.H_72Q
MHLKZ/C4,Y]*[+FPC^M32ZIO^<@X?UQRG=<HZ'U3I-O3LK(W>F\V-MJ(:"[?6
M]@;O:Z/_`$HNF(T5'J'2<?J%V'?82R[I]XOHL;]+B+*O^*N9['I*;S>/'S0.
MH9E6!AY&;<?T6-6ZU_;1HW;1_61YTXY[+G/K*#U3J>!]66R<?)#\OJ1:8(QJ
MO;35_P"A.6ZMO_6DE.E]7>L,ZUTC'ZDUHJ-S3ZE.[=Z;P8?4YT-]S5I+@OJ#
ME6X'5NJ?5_)^FVQ]M0[;F'T[=O\`QM?I6KO6\)*?_]#J\5Y%CS[?INU/;57\
MJNRZJNW&`M-#CO:QNT&1,U_O[%EWUV8N8^JT1+BYI.F]I,^U6J<\@;W&"&[*
MP#HV='$?RESF#)&''ARZ<1K3^IJ)-Z<2>&4=6YCY&3>/38QS&R"Y[A`'^<H9
MUC'%PKV$\%FR'`CG>H6Y^^&NES36`03PX?GM_E*AE91>-UCM&C5YTT_EJ7-S
M$1BX`3/Q*V.,F5R'#3K?5XS3D'_A?X+6Y$>*R^@TV589LL!:;W;VM/9O#?\`
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M3`P<O+RK',8Y]=3A6P`MM-GKOVUV;8V^Q)3F?5_HO4L[ZHUY/2NHY.'G3::J
MF/B@EKW_`*/TG-]GJ_Z7_2(G^+GJ6'.3T^^D4]9+G/MR;-;[P'?I6WVO][LC
M%?['U?\`7%;^I>==TWI]'1>H=/R\7(]5X98ZDNJ=ZCG6M?ZS-S:_I?GJE]=/
MJ[GX_4Z?K#T*M[L@V--[*&[G-M;[69+6#Z5=S/T&8DIU/\8U#[?JVY[)BB^J
MU\=FR6;_`.SO5CZAY%5WU6PPSG'WTO'@YKW;I4^G=9'5JAT_JG3,G"OR6.;=
M1?4321'Z0-R637M?_+]ZP<3I77_J7GVV=.HLZST/)(-M-9'VBN/H.97_`(5]
M;/9[?Y])3WDIB]@:7$@-;J2>!'BL2OZX]`>R7WV4OX=5;1:VQI_=<STUB]<Z
MAU;ZR&GI'3^FY=?2,FYC<_.N8:M](=N?7379LM])^W]);M24]FY[`TN+@&@;
MBZ=-O[VY<?T!O7>IY&=]9>GV8K*NJ6AF-]I8][ABX^ZFGT_2>S9Z[_4M<Q%^
MM_5L^[IV5T;HG3\N^ZP&B[(KJ+:ZZR-MOI6/V^J]S/8STUL_5_*Q+.GUXN)C
MW8C<%C*33D5.J+8;Q[@&V?UZTE/$_66OJ70?K'@]?RG4FRYP-KL9KF-(J'IY
M%;FV.>YS[L:S_P`#7I-=C'L;8PAS'@.:X=P=6E<G]?7-S^GOZ7CX>3E]0J?7
M=1Z51+`9]SO7=^B_F39[=RC]5NMY^!T^GIG6>FYM#\<"O'R?2=8Q["=M;7NJ
MW^G96WV>])3_`/_1]-OQ,?):&WUML`XD:C^JY5OV%TSCT?\`I._O6A"4**>#
M',W.$9'O(6D2(T!+0/1.F]ZO^D[^]/7T;IU;P]E(+@9&XEP!\=KE>A)`<K@!
ML8H#_!">.7<L8(_N0,W-9A4&^QKGB0P-8))<X[6<_P`I63HLG/L.1U*G&80*
M\,?:,A[OHL,'T7/_`#7.;[K&M4RUU&DD#<(,"6SP4*K*KLR+<9C7A]&W<2"&
MG=K['_GJM@Y-SNGF_(>#!>YEKQM!K'T+GM;^\U1P\NYO3+,W-<X@[K6L<T-<
MVL_S=;FC]Y)3HSYIIC3\5E49><,G!;>?TF:'OMQ@!MKK#=S8=_)<?[:EU`/R
MNI8^$'EE-3?M=CV:.!:=M0GZ.W>DIU-3P56Q,ZO*LO8QKV_9G^F][Q$N&KMJ
MK8'47NZ-^T,LCVM>]SP(#FL+O3?M_EL"J8W[0QL;!(=LORKBZV@PXN;9-MUM
MGYVZIO[G\VDIW9GNEYA5,G,V6FEA`+&^I?:[Z-=?\K_A7_X-B'TRS*R,=^5:
M[=Z[B[&K>-NVL>VO=M_TG\XDIT)[SPF^)63T^WJ.=4;VY.RD7GTG[!-E33M<
MTC\UG[C_`*:)FY.6WJ&-C8SFC=-MS2)`J&CK+7_F[G?S>U)3I?D26#5G]1NJ
M'I7$_:<C;A.+1+JFG]-;:W\W'V_0_P`(M7+R75N932W?D6SZ;3]%H'T[K?W:
MV?\`324V9'$IQ*SNFWWY5^1?ZF_$:?2QY``<6_SUWM_,]3VU+1`@>/FDI__2
M]527RJDDI^JDE\JI)*?JDK.LP^G'(R+[+O:2W[347@5[@!Z9M;_WUZ^9TDE/
MU!G48U^'95D6>GCN`WN#@T!H,_3_`'')/JPOL=E3RW[*6D6$NT@_2+K)7R^D
MDI^G,7&PZ+W%MOJY3JV[B]P=8*A]#:UOT:MRI8V/7DV9M^8]U#[7Q=3N#2,=
M@+:?6UW5,L_2/W^Q?."22GZ>R:<&["#+G-9AC8Z0X-9M:6NJ;N^CZ3O:E7C8
M]667OM-F1;N-8L<"6L.WU&8[?S:MR^84DE/TOEX/3;+<FR^XM]1K67M]0-:T
MQ^B>YOYMG^CWJPS'QOLCZ6/_`$)86O>':Q$%_J?F^U?,"22GZDQF8[<>MM!:
M:&M`K+2"-H_E#Z2J6X?3G'-;9;#[V@Y9W@.;6!#6_P#`T[5\S))*?IG[+TPY
M%-_J"6T[**@\;#5^:]C/SOZZGDXN%;E^M=86VLI<U[`_:#4?IFUD_0:[\Y?,
M:22GZ?Z=CXF/0VO%L]5@:-K]P>2W79[F_F?N*VOE5))3_]D`.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X
M0DE-!`8```````<`"`````$!`/_A#R5H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS
M>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP
M9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W`O,2XP+R(@>&UP.D-R96%T941A=&4](C(P,3,M,3(M,#54,#DZ
M,CDZ-#8B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9TPJX@3V9F:6-E(%=O
M<F0@,C`P-R(@>&UP.DUO9&EF>41A=&4](C(P,3,M,3(M,#54,#DZ,S$Z,S,K
M,#4Z,S`B('AM<#I-971A9&%T841A=&4](C(P,3,M,3(M,#54,#DZ,S$Z,S,K
M,#4Z,S`B('!D9CI0<F]D=6-E<CTB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@
M,C`P-R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!-33I$;V-U;65N=$E$
M/2)X;7`N9&ED.D$Y1D-!1$4W-C$U1$4S,3%!.$-!144Y,31&1#=&141!(B!X
M;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D%!1D-!1$4W-C$U1$4S,3%!.$-!
M144Y,31&1#=&141!(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD
M:60Z03E&0T%$13<V,35$13,Q,4$X0T%%13DQ-$9$-T9%1$$B('!H;W1O<VAO
M<#I#;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%
M0S8Q.38V+3(N,2(^(#QD8SIC<F5A=&]R/B`\<F1F.E-E<3X@/')D9CIL:3Y*
M86-K:64@36ER;VYE<V-U/"]R9&8Z;&D^(#PO<F1F.E-E<3X@/"]D8SIC<F5A
M=&]R/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)D97)I=F5D(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+VIP96<B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II
M;G-T86YC94E$/2)X;7`N:6ED.D$Y1D-!1$4W-C$U1$4S,3%!.$-!144Y,31&
M1#=&141!(B!S=$5V=#IW:&5N/2(R,#$S+3$R+3`U5#`Y.C,Q.C(S*S`U.C,P
M(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7
M:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B`\<F1F.FQI('-T179T.F%C
M=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z04%&0T%$
M13<V,35$13,Q,4$X0T%%13DQ-$9$-T9%1$$B('-T179T.G=H96X](C(P,3,M
M,3(M,#54,#DZ,S$Z,S,K,#4Z,S`B('-T179T.G-O9G1W87)E06=E;G0](D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D/2(O
M(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B`\>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B+SX@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!
M9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!
M`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__``!$(`#P`K0,!$0`"$0$#$0'_W0`$`!;_Q`&B````!@(#
M`0`````````````'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'
M`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)
M44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%56
M5QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(
MB8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT
M]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"
M@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"
MTN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F
M]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJ
MNLK:ZOK_V@`,`P$``A$#$0`_`-I3Y,?,?=U!N;*=7].54&+EPLHH-Q;MGICD
MJI,A*`RT^$B4E9)5'U/)!]\Q/O(_>PYAV138[$FE`:=OAU)X$U*5_+AU.O(O
MM/$(H+J^CJK@-I;4:`YH:M_Q71;L5V=\D<Y^[!VGNX6`J6^VJ:8WTBS`J5.D
M7O=?Q[Q!V[[PGO)S$A:TCN"I.*-'Z\?+J2]QY,Y=M(U46,%?])Y=*:;=OR0A
MH(9_]+&_+U56`*K3!I`/T4>FWY]B^7W0^\_<`,_.2A?^>6''IP;RX=%"<O\`
M+;Z5-C;_`.\=)3+]N?)+;%=.*KM;=DHI@&`8P5EP;,+A%_/LHF]\??[:"?K.
M?$5ADUM8O+)\SY=&$7(>PW:TCLX0#_1Z/1\5/E=D.UJ^KZ[[&ABH-[8^A2LQ
MF1HX'HH,]2BR&54D(49=0+M&.+<^\Y/NL_>U_P!<R2'ER^A#7H[`25[F&"V(
MQ\1S0GY=0WSW[=S[+$\JH1%6IXX'D1DT`ZL#B(DCT@D_0@DFY_%C_C_7WGRZ
M*9V6;XB.'_%=11;H8*QMY$]3"`JD<\W^GUO;\?T/MSJW5=OS"_F!=7?#+LOX
MO]<[ZIY,A6_)+LF/9G\0@K(J1-A8>2-:%=^;@BDU/68V3+54%$`MAY&X_P`?
M=>ZL/1M*Z3SIX!%K$?4'B_U!O[]U[I/YZJK<=A\E7XS'5F9KL=CLAD*'$455
M'2RY>NABDEAQ"2N;+-42J%5F](+<^_=>ZI1[<_GA[,^-.:Q>WOE%\-_E7T=F
ML[19/([>7,X/:V?PV;IL2S+DGPV=PV<:EJFC7G38$@CZ>_=>Z$O97\U#?W:F
MS\;V5U!_+A^:6^NM\Q0C)XW=/\&V1MRJR^.D7]O(X3`9C<\=7FEE`NOB)9OP
M/?NO="9\3OYK/Q5^6>^LET]MS-[MZQ[^P<E90YWHONO;E1L3L"BR&)=TK<?C
M:;(:*#,9"G8!F6&1W()-K"_OW7NK,EJ(O'8DK92"".0?Z6/Y)_WGW[KW1+OE
MG\_/B]\(-N4&:^0G8\6W<OF;1[5V#A(7W'V1N^0L(XH=O[(Q7ER%7)+,P0&P
M34;:AS;W7NBI[>^>WSD[AQ$.Z>A?Y8/9,.T,@GW>(SWR#[<V9T_E\WBG4O'/
M!L^:FRN?Q#RIRB3CDD?Z_OW7N@![I_G;;T^)>1P>(^97\OGY`])1YK[;^&[V
MP&[-K=A;`RU1/*E.*/'[CQ$,=)/DXO)J>BJ"LR)<VO[]U[J]'9^Y*3=VWMO;
MMH9/)B=W[?P&Z</'-Z9*7&9O%192F\G]79)A_K'W[KW2KJ;^*ZRF$A20!8%N
M+Z0;@AC]/]?W[KW5?&?_`)@'6F"_F"[+_E^38ZJ&_-T]/U_9]3N^HRU-1X/"
MY<5!;`[$_ASL),IGLUBH):M0C7\8''X]^Z]U87&"$BOP0MB#];VYX]^Z]UF]
M^Z]U_]"\?;V"K=P;MW)52UA-54[KRP5IYT1@RY(A3>P:X`M_6WOYN)]HYWYQ
MY@\*\C9D\9QE5X:SZ-UG#<2W%I;J4P=`]/0='PV#UM245/\`WBS--2;7KL$I
MK,^)86_NQF\&>#6).?2F<`-Q&#8G\>^B/M-[=G8]F@-UMRF31FJKPIGC7J%N
M:-\OQ,5U^?\`J_+H6</M[86;QV%BQ0KGQN'S-?7XO+5%,[4^7ED4MXLJ2H"0
MQN_!L!8?3W*/+6R<C<T)-#;;'(2"PKXIS0Y\A_L=`^[W/=+9E9G.H@8\ORZ`
M?LWJBHHXZQ*#'M7YAR\N:W94?MX&@C8ET3#L+),54@?GGWCE[U>PMG+,\MCL
MTX0DG$K<./\`$.AGRUS)?N(P7S5?3U'0`?'O%RXWY,=?^*:GK#5U63%6=9].
MG'L`PYXY%_<0?=2.V<J_>.V_8HSV>*J$5/&E?/S!QU)/NWNT,NW2HHHQA_Y]
M^SJ\F-O'H)^B@W_UR;>^WT[/)OT"*>P*?^.UZP^E7QIW51FO4EVB$Q65M+%6
M8$L%4:59BUR;#2HO_A[,^J=:2_\`-(VSO+YK]=_(?^9)MBKKDZZ^/O=F.^-?
M3%$JR&+_`$8[&RL--O/M90;HM)E.TZJ*6-N&"0V!L./=>ZV>/Y;7R6B^6'PN
MZ([AEK(JC<[[5IMG=@RJVHQ;WV='%A,^DFH_YS,3T\=8O]$J%]^Z]T?6PD-Q
M8$<W'!!_/^QY]^Z]UJS?\*AHXTZ4^+!+6=.R>PD$O^[O&=D$Z!-_G-%P+K?3
MP../?NO=7S_!]WD^%_Q3*,R_\8!ZJ/HLI.G:&&%["UR2/]N>??NO=:F?\Y+%
M3XS^<MU">DZ&I/;V23HG.8^DVU&JY67?,NY(Z=Y46GTRR9&KVN"\J$D2)ZFO
M[]U[K;:^7OR/P?Q-^-W:_P`@=SPQUL/7VUWKL=C+C3G-V5`3&X+$`KSI?-3+
MY0I#"/41R/?NO=:W7\E#XY9GYI=Z=R?S-?EK)4=F;XP6\:C!=9?WHC^]P.-W
M;)1*,[D=N8<K+#2[8VCC334.+I45#J!D/J'OW7NMN-:=Y4O)(Q=A<,;$K?FX
M'T%CR!]![]U[HM_RF^.&P/ECT+V1\?NR<=!7;?["V[7X^FGG2*23!9VG267#
M;HH)]'DI<G190QRGQ%7T!UN`S7]U[I7="[%SG5G3/5G6VZMPP;IW'UUL/;>S
M,YN6&F:CAS51M[#T]%_$X8I+,L,T<0]/X)/OW7NE/V;V)M;JKKK?7:>\:Q:'
M:/7FV,WO#<E6SJ#3XW;>,ERL\*!O3YY8X]*C^TQ`_/OW7NM%;Y<X/O?K.H^(
M'\WW=%3F:+L3Y-=Q5_;-7AW@:,];X7;>9%;T_M)N04@R'443*0-*.[M<&Q]^
MZ]UO-=4]E[=[>V%L#M/9T\=9MKL#9^'WCAZN-M8?&[@I(:PT8)L&J(*R2S$?
MD$#CW[KW0L>_=>Z__]&_;8$F+&Y\V:O'Y!R-PYBWVLB2>K^)M:W'Y/OY[N4X
M+6QN?I!<$SFYD/Q-7,I]<_SZS+W6)Y=K.DGX!Y_(?/HXG<,.3I^DZ&6@Q>6H
MJ"@W)BLWE<35[@DS%=#B`3)+E8<53H:FBI!D0`4FNEOQ;WG/[NQ;AO\`[)[9
ML^TO(MRC1L3&Q5J*RDDE2K4H,U/RZA?9;U++>IC.BL]`@)6M*DXJ:@\:T'SZ
M<MA]]8"AVT<>L]#51Y.C^UBHU9`QF=2H(4#AV9N?S[3>W?NYO$][;P26"HH5
M5-%B'P@+7`\Z9_GT8\P\A;=9*9(;LDG/Q.>.:9_R=+??)J<GLC!RYK$Y>MDI
M:0MDJ''9>"AI,$I!\;UF,8B9[I8W:_L>>ZF]-NNVZI"5(1N&.`KY=!C;UDL)
M"($KPSZ_F>B;],/CG^3W6QI(9J8?Q?)BT\\=3J`Q[$#]K^O^/O#;V`>.;[T'
MM&RJ*F6^K@9I;24KZD>5:TXCJ9N:HO#]MIWD%9##Q.3D^ISU=8HNX_H;G_>?
M?:[25W=V/I_S[UB/$P;;]5<U_P"?NJU_YK?R7SGQH^'78N2Z_-56=Q]O55!T
M3TCBZ(I)EYNQ>SM6WJ*KQ-.`9)FP5%/)7#3^EHP20/9ET[T2795+O?:GP:@^
M!<W\M;Y.Y7:$W3YV%N7/U-?UH(,]NW/8UJK.[VEG&=435S;SD;(>KU)900=-
MO?NO=$>_X3L=Q;GZB[H^0OP1[,\V`RGDKMY[3VKE@RUF,WGLJ<83?6WUC<D)
M40T4<59*%`N(;F]O?NO=;=L7^:Y-^#<_UXY/OW7NM63_`(5!_:CICXH+/#+4
MTW^DWL`GPL0[#^Y%R%_!8_C_`!]^Z]TZ=D]Z_P`UKX>_R[^F>]>I<O\`'+L?
MJ+$],]<G(TM+L/<LN]NHMI5NUL1#A]QY:/[^6BW72XUI43*.J1^&52;%06]^
MZ]T*W\DSK[XO]^[=W!\Y,KF-P=V?/#(YF7#]Y;S[4K*>OS'76XJA)#1T'7^$
MC08_:NR,O@PDF/GA5W:+4%90IO[KW0Q_\*"*'+5/\N?<+89"U%1]N=<U^702
M$%J0Y>I=#*`0'C;*RHI!N#<>_=>ZY?\`">^HPM1_+HVO08MX5R6*[3[';<24
MS:_'EJS(AW4O<DD(X`!_3IX]^Z]U>G[]U[J,88+<#Z7(^O!MR1<<$WY_K[]U
M[KS)>$C2"=)`!'^T&PY^@O\`[;W[KW5&?\YKLS=VY]L=$_!SJS`;DWYOKY4]
MDXJO["V7L.>"#=4WQTZTJ(=Q]BK!5Y!X:7'/N-Z%*(5$UHY%$B'Z^_=>Z`_^
M8EF.U?EQ\*-Y]%4G\N;Y(]<C9V+QVZ.L\UDJK8,>,V3-URG^X>KJ<;CLM65+
M8QMO4D\/V<?[FE@#^FQ]U[I2?\)W/DX_;7Q1W+T%GZXU6Y/CCNIJ';7FD`KZ
MOJ_=:R9;;Q6)O6O\#R[UE)(;Z0="V'OW7NMB'W[KW7__TKN:3*UFU-Z;GQ<\
MD^-KDW/EJ66CD7]RA\F1)5W_`#Z@;CW\WF[[1NW*GN+%:3,VGQB],\"2?,]9
MT[+;C<ML:HJI4#^7^#H[75G:N.Q\]'CJ&HB6EEC,^\<_DK5=;E:+%ABV"ACJ
M?(;R%[%?Z'WFC[;>\NVW>\P\K[C1D6+()7("UI0@^E>H7WWE]4W"8"@>I(XX
M/"O2ZQF?ZJPKXC==%LC9N,RV>S6?H:O*408O@+*3#-0450IIZB8W#&R`*WT]
MCL\W\H;?=,]I`BMJ/`C&?+MZ#4^T\PU1;F=BH'G7(^9KT"?:/9D671UR,\?]
MXZ?5009JFG:&DW%C%)97RT43+'$P``Y'N"O>CWB@@MPD+@*0!Q'GCTZD7E38
M;;PU%PH^SH-_C;D,AN7Y,=?U4<$4TM%)DLE7SPJD<6.QBX]E#N%`')'!/L+?
M=EG$WWG/9]68>(SWQ`\S_B<AQT)O<F+Z;VSNF.$"D5\OBQU=^SVIWEN@72QG
M::H%/31HIN9/(WTTKR?Q_7WW3:,+NT9SD>E3P]//K"C;I/%VHU(KJ/\`Q[U]
M.M?BJ[9V-\]_YTNP>LL-O#;NY.E_@!L3,]D8^EH,MCZG'[O[\W&4PLDU`%J)
M8LZVQXC^X85<1.I8$<GW;HPZV%A,)+2ZG$087%V!#_0K_47)M_K<>_=>ZTK_
M`.:9!_L@W\X3JWY;;4S<'\'WU5[2[>W3A,54T/W]%2XRK&SM_4%1B(YHZR==
MS8PM4.;6FL2US[]U[K<$ZN[;ZZ[JV5@NT>JMWX7>NQ=V8ZGR.!W!@LK%6T53
M#41"3[;P1N30Y=&)5XI+.K*0P!X]^Z]UK.?\*?\`<^W)>N?B[LJ'-X>3=R[O
MW_GJC:WWM%-G*'"/MA,?'N!J,3K**3^(S*A:VDD$>_=>ZO0^#]7L#M3X&_'7
M$-4;>W]M#*_'K9&T-ST5)-CLKB<DB;/I,-G\)DJ**20(Q9)$E0V:_P!;<'W[
MKW6J3N>C[._D0_S)8,W@8,ON#XU]FEY*:BD:7^'[QZ*S67/\0P%3*`D,F_>H
M:EFGHU*%Y::)%_0]C[KW6VEO7%?'_P#F&?%7=^SL#O7;O874W=>S9\?CMU;5
MR=%DY,75UZ?<8/*?;0,\N*S.VZX1/+')XY0T)#!23;W7NM9_^7AWMOW^39\F
MNQ_AS\Y,=4;%Z2[>W-_$=B=O5,4C[%.[J5H\91;U@RWIAI]J[KPZ1)60+:2E
MK!J?\W]U[K<,P.<Q.Y<1CMP;;R6.W!M_+TD=7B,U@*ZCRN(RV-D4-!44E=!/
M)!)'(/HR,RW_`#Q[]U[HL_RT^8_1/PIZQSW;7>V],/MNAH<74U&%VJ<I3C=&
M]\I'%.U/@]LX&:4553D)ID5'G16A5"2UA[]U[H"?Y<G<?9O9/PMP?R9^4N],
M?05':N:WIVY1_P`3J<=@L#UKU94YBKEV5M457DC@DI,%@:16EG=M4KL2W^/N
MO=$A_EL[UVU\Y_YA7S6^>]+N*@S.VNNXL+\8_CIB(\K#-)3]?XI'K-P;U.*5
MI):*+>.;#E)/3K5B+GW[KW5_$TM+.C4M25EAE5J2J6K&B.IAF5HIHGCX5P8V
M(L>/?NO=:1'1?9FU/Y57\ZOM7K_)[QPN.Z%W7N[);$W355&9@:EVOLKLM4W=
MLD918G'VK;1W#4_Y0S@-'&]C8#W[KW6ZU_>K;7]VSO+^]NWO[HF@&8&[OX[B
M?[K?P(*2:L9?[C[#^&>,@F?R:=5O5;W[KW7_T]OOY`_#['=JY==Y;)S=+LW>
M4A896.>B%7CMS+'S&*XH;T\IM^M?5?D^\'?>W[J'MWS]:/+R[<3KO35RL\M2
M3Z:149X]P'4F\J>Y%WLQ2*8.85P.&`/(BM.BP4/PJ^0^.BJXH\OLI34LQ4G(
M52E6-P2#XK@L!S;D^\3.7_N,^['+=Y+-M&YH%-:-(DTC4./B,E?Y]25-[U6;
M(/\`=>A;U,<?^$CI^_V4+Y%FCHZ=J_9C&C8NNK(U+!78>J1;QD*S#ZGZG\^U
MC?<Q^\"22>;+#)_Y1I_^MG3/^O%9&FJQ4_\`-I/\W3#5_"'O_(U0>MR6Q?MY
M1_E0-;6L$'^MHY`^I`^OMJ3[E'OS/03<P[7(?Z=G(W_'G/Y>G5E]X[1/ALP/
MLC0?Y.CG?&_XRX#HBER&2K<H=V[WS]XLIN"HIA3FDC*V&(VY3!2*;%"]M;W)
MM<G\>\[ONY?=KV[V@L%N;R-)]YTG]1PS21,WQE'D!=0:D45@:8X=13S5S7/O
M"F)I9%M*DA"U0U?XEK04/`#\^A)[QZ%ZQ^1>S!UWVC39W*;9?)PY8X[#;HS6
MV*B:KQH(^WDR6#JL?624AN0\?D"N/>1]I-)%NDOADM2H%<TQ\^H\A`8$K\/I
MY?LZ*8W\I;^770#'Q;<^.VW=EYG%1O74>?V1N'<VU-T@NZR3M-G,1GH<Q.T\
MGJDUEA(>6O[,>GNK!H]KT$>VX-IQO,FWX\&=LZ35U#9&3$-BQC%@:NU_<?Q`
M(+F?5Y=7JOJ]^Z]U7]!_*._E\5-=+E-T?'7"[ZW$R.O]X.P=R[NWGN*.!W,K
M009/*YF=X*=G:_C1@G/T]^Z]T)/3_P#+N^(_Q[W%F]S](=7R]:5>X<!E=M97
M%[8W;N>AVTV.SBLF1:EV_-EJG$4F4C4G1410QSQG]+`^_=>Z#.A_E%?R\H:\
MY?-_'/![_P`T\4L<.=[%W!NO>^7AAF<RRT]/59K.54]/32.UVC32A_(]^Z]T
M(O3G\NWXB?';L&A[)Z/ZNJ.M-Q8Q,O3TN*VWNW=%)M-ES4`.0_WZ]7EJK!.4
M4^@B`%#]/?NO="9\A?B?\=?EG@-O;6^0O6^#[1Q6S<T-PX&AS+U*5^#S<BLD
MU1Y\95T]3%#4QA0Z%M#@"ZFP]^Z]T&_5_P#+C^'?1F_\+V9TSU%!U9N'`O//
M24VRMR[GP^W9&JJ/[*5LAM09:7!UCR+>Y>`MK):]S[]U[HP'<O0/3/R"VM+L
MKO3K'9O:FTJI7'\&WC@J+,"D,JCRFDK)%6HH]9M=H71N!SP/?NO=$9P?\I7X
MU[%BFQ_3N^ODKTEMVI2PV-UIWKNO&[-I([W$>-P>4DR:8^)3R%@D1?Z#W[KW
M3O0?RC_@I+GWW1V)U3D/D!O2:C^SDW7WUO;=/9>9BC`(<T,6=R/\,QY=2;FG
MAC-O]O[]U[H:NUO@C\7>Z=N;$V)V+UBF3Z\ZPQ(PNRNM\7GL_A-EPXBP4460
MVYA*^@I,A%&`%T5!D4J.0?S[KW0?[6_E<?!GKS=^W-\]:=(8[J[<.V<O0YO'
MU'7.Y]U[6I*RMQWIABS.+H,LE#E*6(\^*>-U)_I[]U[HXG:?5^T^X]B[AZ[W
MW!DJC;.YJ>.GRU/B,O78+(1Q1ND@>CS&+GI*^E+-$+M'(IY/OW7NB-+_`"B/
MY<>BMES'Q8V+NC)Y5"N3W#NFIS^Z-S9+4GBU9#+Y7*5%16%8_2&=V(7Z?0>_
M=>ZY1_REO@O'M:KV*G5>>_N+6R8XS[$/9?8;;1,.,7*"DHTQ)W$8HL8%RTX>
M!0(GNNI3H6WNO=?_U-^]4<?A+?FRVO\`U^A_/M,IA4U%B5^=%Z=`C444'KJ5
M=-CZ1_B5_K^/>IDW)S_BEQ&J^C*3_@/51&LOQ5_(]=Z9/\/]M_QOW7Q#_P`H
M\W[>K=GJ?V]8?&#_`&R0?]<@_P#)WO>L_P#*+-^W_9ZW1?\`4>LGAN=2A+V*
MAM`N%_U(/!T_X>[W$EX.R(C2?]7KQZ2&-GR[GIIR,])C*2HR.0G%-08VEKJV
MNJ6.E$@B4O(+\6/C4_3D^]0F*PC::=@&-,GU/V]74"($GJNSXR]C["H=U;EW
M+N+-9"BW?WMOG*OL/&5QR.6I<'LO&3&GV]BDS!>2AI:[)RAJDTFI9S&1Z2/H
MIZMT:7O_`'UL#";$S&WM];KR^TX-WFBVY#D-I+--N:D?,UW\.IJVECI0]11N
M:I@/*HU)_L/?NO=+6?*;=Z=Z]Q\>XMT5*X;:N(H,;4;CW#-)59G(U$4:)CHA
M'S+ELW7L+>-`7=C]#[]U[J1L7LO;G8JY?^[-14QUFWZJFI,_A,G0R8S+XJHK
MZ05^.^ZI:@!XS54[ZA<>I;_T]^Z]T`>^/E-M+8G;,FRI:$5VRMO[2K-S=C[Z
MQL-9E$V-D6R:TN(Q^56F$@IUFF=YF)^D0^EA[]U[HQ^7W;@J/9>5WM65M/-M
MJFVQ4[B;,03!(JS`'%29"&KI'#!4DFC8!2+?J']1[]U[HC'Q+[$V+L'96U\9
MN[<F8CWSW9N7,[FH),G'DLK38ZIR=4ZXC:E1GIC-2+F5Q*I(*77>[$Z1:Y]U
M[H_N5S^,V[0U&1RN4I:.CI91!-6UDL<:5%0P?1CX2SC55EA95'J9N`/K[]U[
MI`;1[BV7OK<VZ-G;6JZJNR^S*/'U.Y)JK&U%%B\;)EE,D-,]34K;^*!>6@_L
MKS]/?NO=)3/?*'IK;-7N_'9+<\DU;L+&0UVX*+'8?(5\PI)65$J<-%3PL<W"
MCGU/3>15`N2/?NO=+//=N;)VOLBE[#SV<:BVE4XJ+-4=4U%4G(UT#+]YJI\4
M$:LL*=Q<6X'UX]^Z]TD*;Y-].U>9VSA4W0YJMXX49_;4ZX^I.,R$+*SBCIJI
M04J,T%-FIA=@?Q[]U[I<]<]J;.[5P-;N3960J:[&8[+9'!Y%JG'5-!7T.6Q+
M^&MIJBCJ$C=&O_4#Z^_=>Z;.P>Y]@=88[,Y'=^X*?')@Z.&JS245)492IQU/
M5,D6(_B4$*R&BDK3*!'K"AW/''OW7NA`Q67CS.+Q&4IHZM(<M3T%=2TU=`T%
M>(9H@]\C"PO2N%;D6'/'OW7NE1I7ZZ5O_6P]^Z]U_]7?X]^Z]UU8'Z@'W[KU
M3UW[]U[KJP_H/]M[W4^O7NN+_IXXOQQQ]0?Z>]=>Z*+\QLKN'$]&YJAVR,C"
MFYLM@-JYS-8N@JLQ4[8VOD<@L>9S%/C*776U,L%,&74`?U7/T'O3*KBCJ"/G
MGKQS@\.D=UMU=3[AK^M3AL)/M+H_IK1EMD+DZ*2EW5V%O`0+"=VY:EEB$M'A
M::-F*&114N_^I6RKOKW3=V0F5[#^3FQ]G1;/S-=MKK*DH-XYS)4N/6BP^Z]X
M9=[8F',YBHA9)MM;=H_\N:GB8L:KT$>_=>Z?/DC0I)W!\?=Q;VI<M7]3[-K=
MP;LKCB:"IR5-%O\`Q=!?:WWN/I(YIIX9=;")75D\GY')]^Z]T^_';;FX\;4=
MP=]=F4M3MO*=K9_^\M-@LI*C2[1Z^VOC328./)+$WB2J?%0^1[C6HM^+^_=>
MZ)WM"ORG:76G>U)M#;V1;L_Y7[YR,-)15F(:FQ&V.J8)WP6/W/F\JL*T<V#?
M"?=/&(F\TDLZ6'U/OW7NC6_(':6X*/H[KKX]["3)U-1OBOV7U-7YZFHC-2XG
M8V*HHAN?-9*1`R4,,V&QK0(UQ>:9>??NO=)_;.V-K]H[CZBPNP=LY;`]+=`9
M'(YR2LS&+K,-E<QV%@7EVW08B"EKDC?(TU/`)ZJKJW4F8R)XFM;W[KW37VOV
M+N6'NK?-!/LS/;LINK]C#<?7.VH,-.VS\]N:NB-5D]U;EKO$T57D<#%:GHJ5
M+O(VIELY##W7NA%^)>*R>,ZIK<]NO'91]Q[_`,OE.P=U97-4BT]5N;(YE):F
MMIJ'%2%:VBIZ&-/%##,/0.``#[]U[IF^,O7537[B[.[WWI@'QN8[`S\V,V5M
M[)T"15&TNN,,S4V+HQBY$\5'+6J"T@C5=0M>]_?NO=3_`)-XC</8]5L'H3;>
M(KJ&GWW6R9#?.^:6A3[79G76#(.0I*.NLL='F-PZ!%%"C)9+CZ?3W7NBU9^F
MR>`_OQWM0]<9:DP/3-)'TO\`&#9+X26LDAR+L*'-=JU^(IXQ+*7EEU4\\J.U
MD/JOS[]U[HS^U*+<'27Q;RM9M_;&:R6\<#M[*[C%)7".LSF[-W9=AE9=RUT4
M>J>:M>NJ&/VS7N(PEK6M[KW14WARV\<MTCUZVRM^9+9V[Q1]P]F;AS^%J*3<
M/;.],8RU$>VL[72,(]O[=QF5;4*:H81$0JBKQ<^Z]U;=3F1HX99(D2>5%\^D
M6*D`G3J/)"'CW[KW4KW[KW7_UM_CW[KW7O?NO=>]^Z]U[W[KW7N/S_7C_7_X
MK[]U[J(^G5^WI\NOU:/'K\6HZM6KGQZOK_C[]U[K@^G7Z_)JL?Z_3\VMQI_U
MN/?NO=9S?1S;3_C;^HM_O/OW7NL`\=_[/^<6VKQ_YVPT6U_[MT_3\V]^Z]T6
M?Y=_Q;_0'VM_=_\`BUO[GY'^\']V_P"'?QW^#:1]]]A_$OV/-]AY?K_NO5_A
M[]U[H3NIO[O?Z+.N_P"Z7B_N[_H^VQ_`O#]GY?X9_"J'Q>3Q_MW_`..FG]O7
M?W[KW0BC3J?]?CT'7?3H\?-[W_LWO?\`XI[]U[KH?\"*?RZ]>KC7X[>3QGZ:
M?]V^+Z_VM/OW7NL\UO(-7Z=47T\7ZM?[%[^K_.?I_P`?I[]U[K@_C\CZM/GL
M=%_'Y=-EOXO[6F]K^_=>ZD1Z/,U]/FT^J^GR:>+?3G3_`$_'OW7NO2:?7:WU
M7R:=.J]O3K_/Z;6O^/?NO=8_^4QKZM7VO%].FVOU:;\WU6O^/?NO==#Z3?J\
MNM/KH\GZOV[7_L_73?\`Q]^Z]UCD\?CF^X_S7E/DU>/1H_VO_FUY/K_M5_S?
;W[KW4]/TCZW_`#?]7^%_S?W[KW7+W[KW7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
